DeSantis Administration Cautions Against Pfizer, Moderna MRNA Covid Vaccines for Vulnerable Individuals, Cites Concerns Related To Rare Heart Conditions
DeSantis Administration Cautions Against Pfizer, Moderna MRNA Covid Vaccines for Vulnerable Individuals, Cites Concerns Related To Rare Heart Conditions
Florida Governor Ron DeSantis' administration has reportedly issued updated guidance recommending that healthcare providers steer vulnerable patients away from mRNA-based COVID-19 vaccines.
據報道，佛羅里達州州長羅恩·德桑提斯的政府已發佈更新的指導，建議醫療保健提供者將易受傷害的患者轉向非mRNA基因的COVID-19疫苗。
The Florida Health Department is raising concerns about the safety of the mRNA vaccines, pointing to potential risks such as myocarditis and postural orthostatic tachycardia syndrome (POTS), rare heart conditions. This stance contrasts sharply with recommendations from federal health agencies, which continue to endorse mRNA vaccines as safe and effective for all eligible individuals.
佛羅里達州衛生廳對mRNA疫苗的安全性提出了擔憂，指出潛在的風險，如心肌炎和姿勢性直立性心動過速綜合徵（POTS），這是罕見的心臟病。這一立場與聯邦衛生機構的建議形成鮮明對比，後者繼續認可mRNA疫苗對所有符合條件的個體都是安全有效的。
In June, the U.S. CDC recommended using updated 2024-2025 COVID-19 vaccines in individuals six months and older.
六月份，美國疾控中心建議在六個月及以上的個體中使用2024-2025年更新的COVID-19疫苗。
The FDA in August granted emergency use approval for updated mRNA-based COVID-19 vaccines from Moderna Inc. (NASDAQ:MRNA) and Pfizer Inc (NYSE:PFE)/BioNTech SE's (NASDAQ:BNTX), targeting the Omicron variant KP.2 strain.
八月份，FDA批准使用瑞納斯達克公司（MRNA）和輝瑞製藥公司（PFE）/BioNTech SE（BNTX）的更新mRNA基因COVID-19疫苗，針對OMICRON變種KP.2株。
Also Read: Long Covid Remains Diagnostic Mystery, Diagnosis Remains Elusive; National Institutes of Health-Funded Study Shows.
同時閱讀：長期COVID病仍然是一個診斷之謎，診斷仍然難以捉摸–美國國家衛生研究院資助的研究顯示。
The NBC News highlights that the state's health department is advising that individuals aged 65 and older, along with those with underlying health conditions, prioritize access to non-mRNA vaccines and treatments instead.
NBC新聞報道指出，該州衛生部建議65歲及以上的個體以及有基礎健康問題的個體優先獲得非mRNA疫苗和治療。
Earlier this month, the FDA granted Emergency Use Authorization to Novavax Inc.'s (NASDAQ:NVAX) protein-based COVID-19 Vaccine, Adjuvanted (2024-2025 Formula) (NVX-CoV2705) for active immunization to prevent COVID-19 in individuals aged 12 and older.
本月初，FDA授予諾華生物製品公司（NVAX）基於蛋白質的COVID-19疫苗，配合劑（2024-2025配方）（NVX-CoV2705）緊急使用授權，用於防止12歲及以上個體感染COVID-19。
The state's guidance emphasizes that high immunity levels from prior infections, combined with current data, justify their position.
該州的指南強調，來自先前感染的高免疫水平與當前數據相結合，證明了他們的立場。
The report adds that while there is a documented small risk of myocarditis linked to the mRNA vaccines, especially in younger males, studies show most cases are mild and resolve fully.
報告指出，雖然mRNA疫苗與心肌炎之間存在已記錄的小風險，尤其是在年輕男性中，但研究顯示大多數病例都較輕，並完全恢復。
Research published in Nature Cardiovascular Research highlights that individuals infected with COVID-19 are five times more likely to develop POTS than those vaccinated with mRNA vaccines, reinforcing the importance of vaccination.
發表在《自然-心血管研究》的研究強調，與接種mRNA疫苗的人相比，感染COVID-19的個體發展爲POTS的風險增加了五倍，強調了接種疫苗的重要性。
Researchers from the Universities of Cambridge, Bristol, and Edinburgh revealed that COVID-19 vaccinations may significantly reduce the incidence of arterial thromboses, a leading cause of heart attacks and strokes.
劍橋大學、布里斯托大學和愛丁堡大學的研究人員透露，COVID-19疫苗可能會顯著降低動脈血栓症的發病率，這是心臟病發作和中風的主要原因之一。
Price Action: MRNA stock is up 2.37% to $69.90, PFE stock is up 2.12% to $29.89 at the last check on Monday.
股價走勢：MRNA股票上漲2.37%，至69.90美元；PFE股票上漲2.12%，至29.89美元，截至週一最後一次檢查。
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
免責聲明：本內容部分使用人工智能工具生成，並經Benzinga編輯審核發佈。
- BHP Group Sounds Alarm on Copper Supply, AI and EV Growth Could Drive Prices Soaring: Report.
- BHP集團對銅供應發出警報，人工智能和電動汽車的增長可能會推動價格飆升：報告。
Image via Shutterstock
圖片來自shutterstock。
譯文內容由第三人軟體翻譯。